Agios Pharmaceuticals, Inc. announced that Jeffrey Capello has been appointed to its board of directors. The company also announced that Paul Clancy will step down from the board of directors at the end of his term, effective June 13, 2023. Mr. Capello brings to the company deep operational and financial expertise in the healthcare and life science sectors.

Most recently, he was the chief financial officer for Biogen, where he partnered with the executive team to achieve consistent and predictable financial outcomes while enhancing the R&D pipeline and implementing a disciplined capital allocation process. Earlier in his career, Mr. Capello served as a chief financial officer of several leading healthcare companies, including Boston Scientific, PerkinElmer, Ortho Clinical Diagnostics and Beacon Health Options. He has served as a member of the board of directors and chair of the audit committee of several early-stage, publicly held life sciences companies, including Sirtris, OvaScience and Flex Pharma.

He has an MBA from the Harvard Business School and a B.S. in business administration from the University of Vermont. He was a certified public accountant and former collegiate and professional ice hockey player. Mr. Capello commented, Agios has done an extraordinary job of building on its heritage in hematology and cellular metabolism to advance a robust pipeline focused on rare diseases.

I am thrilled to join the board at such a pivotal time for the company, and I look forward to partnering with the rest of the board and the leadership team to help drive value creation for the company to ensure its continued near- and long-term success.